Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL13AP13 is a processed pseudogene of the ribosomal protein L13a (RPL13A) gene. Pseudogenes are sequences similar to functional genes but generally considered nonfunctional due to accumulated mutations that prevent expression of a functional protein. Genes encoding ribosomal proteins, such as RPL13A, typically have multiple processed pseudogenes dispersed throughout the genome. RPL13AP13 itself does not produce a protein and is not a therapeutic target, enzyme, receptor, transporter, or recognized disease-associated gene. Most available research and functional annotation pertain to the parent gene RPL13A, not to its pseudogenes. There are no known drugs, mechanisms of action, or biomarker status for RPL13AP13.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L13a pseudogene 13 (RPL13AP13).